Showing results (121-130 of 167) with videos related to
Sort By:
Pageof 17
American Journal of Clinical Dermatology|March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.Dermatologic Therapy|April 12, 2019
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymesAseem Sharma, Andy Goren, Rachita Dhurat, et al.American Journal of Clinical Dermatology|April 11, 2025
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of TreatmentBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.Dermatology and Therapy|May 22, 2026
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental VitiligoTatjana Lukic, Pranab Ghosh, Lynne Napatalung, et al.The British Journal of Dermatology|September 14, 2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trialsBrett King, Jerry Shapiro, Manabu Ohyama, et al.Dermatology and Therapy|October 14, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia AreataBrett King, Amy McMichael, Rodney Sinclair, et al.The EMBO Journal|February 22, 2008
Perturbed desmosomal cadherin expression in grainy head-like 1-null miceTomasz Wilanowski, Jacinta Caddy, Stephen B Ting, et al.The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.Journal of the American Academy of Dermatology|January 13, 2022
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasisChunlei Zhang, Kexiang Yan, Qingchun Diao, et al.Pageof 17